We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced positive top-line results from a phase III comparative study, evaluating PF-05280586, the company’s biosimilar version of Roche's (RHHBY - Free Report) blockbuster leukemia drug Rituxan/Mabthera (rituximab).
Notably, Rituxan is approved for treating blood cancers including non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia as well as immunological diseases like rheumatoid arthritis.
Shares of Pfizer have gained 18.5% in a year’s time, underperforming the industry’s rally of 23.5%.
The phase III REFLECTION B3281006 study was designed to compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 compared with Rituxan. The study met its primary endpoint demonstrating equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden and follicular lymphoma.
This marks Pfizer’s fifth proposed biosimilar monoclonal antibody (mAb), showing positive trial results.
Significantly, Pfizer's biosimilar capabilities were substantially boosted by the acquisition of Hospira in 2015. In December 2017, the company launched Ixifi, the second biosimilar version of Johnson & Johnson (JNJ - Free Report) /Merck & Co., Inc.’s (MRK - Free Report) blockbuster drug, Remicade, in the United States.
We remind investors that Pfizer is evaluating 14 biosimilar molecules in various developmental stages. Incidentally, biosimilar products in late-stage development include the biosimilar versions of Roche's Avastin and AbbVie's Humira. Also, Herceptin’s biosimilar version is under review in the United States as well as the EU.
Importantly, Novartis and Teva filed regulatory applications last year in the United States for the biosimilar version of Rituxan in September and June respectively.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III
Pfizer Inc. (PFE - Free Report) announced positive top-line results from a phase III comparative study, evaluating PF-05280586, the company’s biosimilar version of Roche's (RHHBY - Free Report) blockbuster leukemia drug Rituxan/Mabthera (rituximab).
Notably, Rituxan is approved for treating blood cancers including non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia as well as immunological diseases like rheumatoid arthritis.
Shares of Pfizer have gained 18.5% in a year’s time, underperforming the industry’s rally of 23.5%.
The phase III REFLECTION B3281006 study was designed to compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 compared with Rituxan. The study met its primary endpoint demonstrating equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden and follicular lymphoma.
This marks Pfizer’s fifth proposed biosimilar monoclonal antibody (mAb), showing positive trial results.
Significantly, Pfizer's biosimilar capabilities were substantially boosted by the acquisition of Hospira in 2015. In December 2017, the company launched Ixifi, the second biosimilar version of Johnson & Johnson (JNJ - Free Report) /Merck & Co., Inc.’s (MRK - Free Report) blockbuster drug, Remicade, in the United States.
We remind investors that Pfizer is evaluating 14 biosimilar molecules in various developmental stages. Incidentally, biosimilar products in late-stage development include the biosimilar versions of Roche's Avastin and AbbVie's Humira. Also, Herceptin’s biosimilar version is under review in the United States as well as the EU.
Importantly, Novartis and Teva filed regulatory applications last year in the United States for the biosimilar version of Rituxan in September and June respectively.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank
Pfizer carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>